Kanuma (sebelipase alfa)
-is an innovative enzyme therapy approved for treatment of patients with lysosomal acid lipase deficiency (LAL-D).
-
LAL-D
-decreased or loss-of-function of the LAL enzyme
-leads to continuous accumulation of cholesteryl esters and triglycerides in the liver, blood vessel walls and other tissue
-can result in progressive complications in multiple organs; liver, spleen, and intestine
-ase
What end suffix refers to enzyme based medications?
-mab
What end suffix refers to monoclonal antibody therapy?
CRYSVITA (burosumab-twza)
first and only FDA- approved treatment for X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older.
Mipomersen
targets human mRNA for apo B-100, the prinicpal lipoprotein of LDL. The binding of this drug to mRNA results in degradation of the mRNA thus inhibiting translation of the apo B-100 protein.
Macugen (pegaptanib sodium injection)
anti-VEGF inhibitor approved by the FDA for the treatment of Wet Age-Related Macular Degeneration. (injected into the eye)
-rsen
AS-ON nucleotides are denoted by what suffix?
-apt
Aptamers are denoted by what in their name?
aptamers
are RNA or DNA nucleic acid drugs that recognize specific proteins. They fold up into unique 3-D structures, allowing them to bind specifically to proteins.
Patisran
doubled-stranded siRNA that causes degradation of mRNA through RNA interference, which results in a reduction of serum TTR protein and TTR protein deposits in tissues.
siRNA
-therapeutics used to target host mRNA
-"kill the messenger"
-NOT CRISPR technology
MELAS
rare progressive neurodegenerative disease caused by the decreased ability of cells to produce sufficient energy in the form of ATP
antioxidants & vitamins
What drugs are most often used to treat MELAS
-tecans
topoisomerase inhibitors include what in their name?
(CAMPTOSAR) Ironotecan
-topoisomerase I inhibitor
-anticancer agent
(ADRIAMYCIN) Doxorubicin
-cause apoptosis of cancer cells by:
-intercalation into DNA
-Topisomerase IIa inhibition
damages cardiomyocytes by inhibiting Topoisomerase 2B
What adverse effects does Doxorubicin have?
550 mg/m2
What is the lifetime dose of Doxorubicin?
-floxacin
How do we identify fluoroquinolone antibiotics?
Fluoroquinolone
inhibits bacterial DNA gyrase and bacterial topoisomerase IV.
Histones
these proteins work to "pack" DNA to protect, but also permit access to the information in the DNA for replication & transcription.
Histone acetyltransferase (HAT)
increases gene activity by creating a more open chromatin
Histone deacetylase
-removes acetyl groups
-leads to gene repression through condensation of chromatin
-"on-off switch"
True
HDAC inhibitors render chromatin "transcriptionally competent" by keeping chromatin in open state. T/F?
HDAC inhibitors
-block erasing of acetyl groups
-causes accumulation of acetylated histones
-induces apoptosis of cancer cells
-inostats
Which stem denotes HDAC inhibitors?
Zn+2
What is one basic structure requirement of all HDAC inhibitors?
DNA ligase
completed fragments that are joined together by this enzyme, catalyses the formation of a phosphodiester bond between the 3; -OH end of one fragment and the 5'-P end of the next.
200 nucleotides
How far apart are RNA primers?
10 nucleotides
How long are RNA primers?
valacyclovir & acyclovir
DNA polymerase inhibitors that are used to treat Herpes Simplex Virus (HSV)?
II, III, IV
Which CFTR mutation classes do we have approved therapeutics for?
Ivacaftor
-CFTR gate potentiator
- first-in-class treatment of CF
-responsive to G551D
Missense
Ivacaftor is used for what type of mutations?
Nonsense mutation
-change in genetic code that results in coding for a stop codon; protein is generally LOF or function is impeded.
nonsense; cannot transport cl ions out of cell
Class 1 CFTR mutations result from what kind of mutations; and how does this affect the protein?
2 copies of F508del mutation; frameshift (in frame)
Orkambi is indicated for patients with what type of gene? What mutation class does this fall under?
Lumacaftor
-acts as a small molecule chaperone for CTF and helps it get to cell surface-referred to as correctors.
ivacaftor & lumacaftor
Orkambi is a combination therapy utilizing what medications?
Trikafta
-first triple combination therapy approved for patients 6 years and older who have at least one F508del mutation in the CFTR gene
Exondys 51 (eteplirsen)
-injection
-antisense oligonucleotide
-for patients who have confirmed mutation of DMD gene
out of frame; in frame
EXONDYS-51 converts _____ to ______
SPINRAZA (nusinersen)
-SM2 AS-ON
-administered by intrathecal injection (spinal)
-binds to exon 7 and increases inclusion forming production of full-length SMN protein
episomes
-standalone DNA constructs that do not integrate into the genome.
-replicate independently of host genome
Zolgensma
-wild-type copy of SMN-dsDNA gene packaged in adeno-associated virus 9 vector
-delivered IV
-delivered to non-dividing cells such as
PARP
-nuclear enzyme that facilitates the repair of DNA single-strand breaks (SSBs) through a process called Base Excision Repair (BER)
double-strand breaks
When PARP's are inhibited, unrepaired SSBs colliding with replication forks give rise to lethal ____
PARP inhibitors
-function in a process termed synthetic lethality
-this drug is used in tumor cells that already have defects in DSB repair pathways
BRCA
-tumor suppressor gene/protein
HR DNA repair pathways
It is known that BRCA1/2 mutation genotypes have defective ___
-paribs
PARP inhibitors are denoted by what suffix?